One way or another they will get the mRNA technology inside every human body.
They tried bribery, manipulation and coercion to persuade every human to receive the experimental injection, but many have refused so now they’re coming for your food.
The New South Wales (NSW) government said on Wednesday that it had requested the American biotechnology company Tiba Biotech to speed up the development of the first mRNA ‘vaccines’ for foot-and-mouth disease (FMD) and lumpy skin disease.
“The NSW Nationals in Government are taking the threat of FMD and Lumpy Skin Disease extremely seriously, and this milestone is another step forward in preparing for a potential outbreak,” said Paul Toole, Deputy Premier and Minister for Regional NSW.
NSW aims to produce a world-first synthetic vaccine for foot-and-mouth disease (FMD) and lumpy skin disease by August 2023 with a $6 million government grant.
Watch:
“I have now written to vaccine manufacturers to take up my challenge to develop both vaccines ready for use and manufacture in NSW by August 1 next year,” Toole said.
“COVID-19 demonstrated to us that all possible avenues in developing vaccines must be explored and we will leave no stone unturned.”
The partnership with Tiba Biotech, according to Agriculture Minister Dugald Saunders, provides New South Wales with an alternative strategy for creating mRNA vaccines against foot-and-mouth disease and lumpy skin disease.
“It is critical that we develop mRNA vaccines for FMD and Lumpy Skin as quickly as possible to protect our State’s livestock sector,” Mr. Saunders said.
“mRNA vaccines are cheaper and quicker to produce, highly effective and very safe,” he claimed.
“Because they are fully synthetic and do not require any animal or microbial products, they do not carry with them the same risks as traditionally derived vaccines.”
Tiba co-founder Peter McGrath said, “Our next generation RNA technology is able to safely and efficiently deliver vaccines for both human and animal health needs and has demonstrated more practical storage requirements than existing RNA technologies.”
From PR Newswire:
Tiba Biotech , a preclinical biopharmaceutical company, today announced it has entered into a five-year, multi-million US dollar agreement with the Australian state government of New South Wales (NSW) to develop next-generation mRNA vaccines against emergency animal diseases that threaten Australia’s livestock industry and domestic food security.
With additional support from the Australian State Government of Queensland, the Australian Federal Department of Agriculture, Fisheries and Forestry, and Meat & Livestock Australia (MLA), this partnership is part of a broader Australian Federal and State initiative to address growing biosecurity concerns, as well as establishing a domestic RNA manufacturing capability, to ensure the region has access to cutting edge vaccines and therapeutics. The international collaboration brings together Tiba Biotech scientists with researchers from the NSW Elizabeth Macarthur Agricultural Institute (EMAI), the Canadian Food Inspection Agency (CFIA), and the Australian Centre for Disease Preparedness.
Australia is a major supplier of animal protein to the international market, generating USD46 billion (AUD72 billion) in annual turnover and providing directly or indirectly over 430,000 jobs, according to MLA. This key sector of the economy, and critical source of food, is under constant threat by emerging infectious diseases. Having already initiated a project earlier this year with leading researchers at the NSW EMAI, Tiba Biotech is working with this network of government, research scientists, industry sponsors and animal health experts to tackle some of the more challenging disease threats.
Millions of people who have refused to get an experimental mRNA ‘vaccine’ may soon be forced to consume the gene therapy in their food.
Research is being conducted at the University of California-Riverside to create plant-based mRNA ‘vaccines.’
Thanks to a $500,000 grant from the National Science Foundation, researchers are now attempting to:
- Successfully deliver DNA containing mRNA vaccines into plant cells, where they can replicate
- Show that plants can actually produce enough mRNA to replace a traditional injection
- Determine the right dosage people will need to eat to properly replace vaccinations.
“Ideally, a single plant would produce enough mRNA to vaccinate a single person,” says Juan Pablo Giraldo, an associate professor in UCR’s Department of Botany and Plant Sciences, in a university release.
